5Green DE, Lester RL, Zifgier DM. Studies on the mechanism of oxidation phosphorylation. Biochem Biophys Acta 1957,23: 516-524.
6Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986,74: 1124-1136.
7Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003,285(2): H579-H588.
8Staat P. Rioufol G, Piot C, Cottin Y, Cung TT. L'HuiUier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M. Postconditioning the human heart. Circulation 2005,112: 2143-2148.
9Lim SY, Davidson SM, Hausenloy DJ, YeUon DM. Preconditioning and postconditioning: The essential role of the mitochondrial permeability transition pore. Cardiovasc Res 2007,75(3): 530-535.
10Bhatnagar A. Beating ischemia: a new feat of EETs? Circ Res 2004, 95: 443-445.
8Qaseem A, Fihn SD, Williams S, et al. Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/ preventive Cardiovascular Nurses Association Society of Thoracic Surgeons ~J~. Ann Intern Med, 2012, 157 (10): 729-734.
9Bonow RO, Mann DL , Zipes DP, et al. Braunwald' s Heart Disease: a textbook of cardiovascular medicine[M~. 9 th ed. Philaelephia, PA: Saunders Elsevier, 2012..1251.
10Massie BM, Krol WF, Ammon SE, et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics [J~. JCard Fail,2004, 10(2) : 101-112.
